NCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
Clinical Trials
105 trialsNCT01932697 2026-02-10
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Mayo Clinic
Phase 2 Completed
NCT05119855 2026-02-05
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01302834 2026-01-12
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT03898167 2025-09-04
PRESTIS
Baylor College of Medicine
Phase NA Completed
NCT04092257 2025-08-06
HPV-Based Screen-and-Treat Demonstration Project in Lilongwe
UNC Lineberger Comprehensive Cancer Center
Phase NA Completed
NCT05453006 2025-07-10
Isbaar
University of Minnesota
Phase NA Completed
NCT04998318 2025-06-24
1:1 Comparison of the Pocket Colposcope in Kenya
Duke University
Phase NA Completed
NCT04772534 2025-05-30
V503-066
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06290206 2025-05-18
PREVENT
University of Utah
Phase NA Completed
NCT01824537 2025-03-19
TRAP-HPV
McGill University
Phase 4 Completed
NCT04587050 2024-12-10
SHiP
Imperial College London
Completed
NCT03487549 2024-11-27
COVE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03981822 2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT04660331 2024-10-09
PROMOTE
Fred Hutchinson Cancer Center
Phase NA Completed
NCT04472377 2024-10-03
HPV Typing Between Self- and Physician-sampled
Hygeia Touch Inc.
Phase NA Completed
NCT02258659 2024-09-24
OPTIMA
University of Chicago
Phase 2 Completed
NCT02135419 2024-07-26
ANCHOR
AIDS Malignancy Consortium
Phase 3 Completed
NCT05340322 2024-07-23
Identification and Treatment of Cervical Abnormalities in Perú Through Integration of Pocket Colposcopy and Telemedicine
Duke University
Phase NA Completed
NCT00667563 2024-03-19
Vaccine Therapy in Preventing HPV in HIV-Positive Women in India
AIDS Malignancy Consortium
Phase 1 Completed
NCT01946139 2023-11-07
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
AIDS Malignancy Consortium
Phase NA Completed
NCT04679675 2023-09-18
STEP
Kaiser Permanente
Phase NA Completed
NCT01084083 2023-06-28
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00380367 2023-05-31
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00973856 2023-01-31
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
Cleveland Clinic Akron General
Phase NA Completed
NCT04191967 2023-01-25
Thermocoagulation for Treatment of Precancerous Cervical Lesions
University of California, San Francisco
Phase NA Completed
NCT01693783 2022-11-08
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00943722 2022-10-03
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01077856 2022-09-13
VIP
Merck Sharp & Dohme LLC
Completed
NCT01101750 2021-01-05
Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
Medstar Health Research Institute
Phase 4 Completed
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT00481767 2020-11-17
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
GlaxoSmithKline
Phase 3 Completed
NCT00947115 2020-10-30
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT03837028 2020-10-06
HPVandFSFI
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Completed
NCT01209325 2020-08-11
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
AIDS Malignancy Consortium
Phase 2 Completed
NCT01164722 2020-08-04
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
AIDS Malignancy Consortium
Phase 3 Completed
NCT01031069 2020-07-21
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
GlaxoSmithKline
Phase 4 Completed
NCT01381575 2020-06-09
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
GlaxoSmithKline
Phase 3 Completed
NCT01627561 2020-04-10
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
GlaxoSmithKline
Phase 3 Completed
NCT03546842 2020-02-25
V503-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00877877 2020-01-18
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
GlaxoSmithKline
Phase 3 Completed
NCT00586339 2020-01-03
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
GlaxoSmithKline
Phase 2 Completed
NCT00637195 2020-01-03
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
GlaxoSmithKline
Phase 3 Completed
NCT00250276 2020-01-02
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
GlaxoSmithKline
Phase 3 Completed
NCT00294047 2020-01-02
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
GlaxoSmithKline
Phase 3 Completed
NCT00359619 2020-01-02
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
GlaxoSmithKline
Phase 2 Completed
NCT00423046 2020-01-02
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00231413 2019-12-12
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
GlaxoSmithKline
Phase 2 Completed
NCT03158220 2019-11-21
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00534638 2019-11-15
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
GlaxoSmithKline
Phase 4 Completed